Delanzomib, a novel proteasome inhibitor, sensitizes breast cancer cells to doxorubicin‐induced apoptosis

BACKGROUND: Delanzomib, a novel proteasome inhibitor, has demonstrated promising efficacy and antitumor ability in human multiple myeloma cell lines and patient‐derived cells. However, the potential therapeutic effects of delanzomib on breast cancer remain unknown. In this study, we show that delanz...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Thorac Cancer
Prif Awduron: Wang, Mopei, Liang, Li, Lu, Jiaxiong, Yu, Yang, Zhao, Yanling, Shi, Zhenfeng, Li, Hui, Xu, Xin, Yan, Yuxian, Niu, Yan, Liu, Zhentao, Shen, Lin, Zhang, Hong
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley & Sons Australia, Ltd 2019
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6449274/
https://ncbi.nlm.nih.gov/pubmed/30883017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13030
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg